Our publications
Emerging Infectious Diseases, Vol. 13, No. 5, May 2007 - Inactivated Whole Virus Influenza A (H5N1) Vaccine
Vajo, Z., Kosa, L., Visontay, I., Jankovics, M., & Jankovics, I. (2007). Inactivated Whole Virus Influenza A (H5N1) Vaccine. Emerging Infectious Diseases, 13(5), 807.
Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval – a useful approach to pandemic vaccine development even in less well developed countries?
Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Jankovics M, Kis A, Jankovics I. 2008 Nov;2(6):221-8.
Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J. 2008 Dec;27(12):1052-6
Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I.
Influenza A (H5N1) pandemic prototype vaccine Fluval. Expert Rev Vaccines. 2009 May;8(5):619-24
Vajo Z.
Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin Vaccine Immunol. 2009 Apr;16(4):437-43.
Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z.